300 related articles for article (PubMed ID: 12972530)
1. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
Younes A; Kadin ME
J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
[TBL] [Abstract][Full Text] [Related]
2. TRAIL and apoptosis induction by TNF-family death receptors.
Wang S; El-Deiry WS
Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders.
Younes A; Aggarwall BB
Cancer; 2003 Aug; 98(3):458-67. PubMed ID: 12879461
[TBL] [Abstract][Full Text] [Related]
4. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.
Grell M; Zimmermann G; Gottfried E; Chen CM; Grünwald U; Huang DC; Wu Lee YH; Dürkop H; Engelmann H; Scheurich P; Wajant H; Strasser A
EMBO J; 1999 Jun; 18(11):3034-43. PubMed ID: 10357816
[TBL] [Abstract][Full Text] [Related]
5. TRAIL and malignant glioma.
Hawkins CJ
Vitam Horm; 2004; 67():427-52. PubMed ID: 15110189
[TBL] [Abstract][Full Text] [Related]
6. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
7. TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX; Ogawa O; Kakehi Y
Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
[TBL] [Abstract][Full Text] [Related]
8. Modulation of TRAIL signaling for cancer therapy.
Fulda S; Debatin KM
Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
[TBL] [Abstract][Full Text] [Related]
9. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
10. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.
Di Pietro R; Zauli G
J Cell Physiol; 2004 Dec; 201(3):331-40. PubMed ID: 15389537
[TBL] [Abstract][Full Text] [Related]
11. A family of ligands for the TNF receptor superfamily.
Cosman D
Stem Cells; 1994 Sep; 12(5):440-55. PubMed ID: 7528588
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
14. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
Odoux C; Albers A
Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
[TBL] [Abstract][Full Text] [Related]
15. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
16. Tumor therapeutics by design: targeting and activation of death receptors.
Wajant H; Gerspach J; Pfizenmaier K
Cytokine Growth Factor Rev; 2005 Feb; 16(1):55-76. PubMed ID: 15733832
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
[TBL] [Abstract][Full Text] [Related]
18. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
19. Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
[TBL] [Abstract][Full Text] [Related]
20. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
